{
    "clinical_study": {
        "@rank": "92565", 
        "arm_group": {
            "arm_group_label": "F-18-FCH & Ga-68-NODAGA-MJ9", 
            "arm_group_type": "Experimental", 
            "description": "1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9"
        }, 
        "brief_summary": {
            "textblock": "Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new\n      PET/CT radiotracer aiming at giving complementary information : more precise images and\n      early localisation of recurrence to standard imaging"
        }, 
        "brief_title": "Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will\n      be proposed to participate to the present study. After signing the patient informed consent,\n      both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval.\n\n      No adverse events are expected."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age : adult patients\n\n          -  Karnofsky : \u2265 80%\n\n          -  Patients with histologically proven prostate cancer for whom 18F-fluocholine PET/CT\n             is indicated for primary cancer staging, or for recurrence with increase of blood\n             PSA. In order to provide a detection probability of 30% or more, a blood PSA 0.5 ng /\n             ml or more in post initial curative intent surgery will be required.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Lack of discernment to sign the consent form\n\n          -  Age <18 years\n\n          -  Patient under hormonal treatment"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111954", 
            "org_study_id": "402/12"
        }, 
        "intervention": {
            "arm_group_label": "F-18-FCH & Ga-68-NODAGA-MJ9", 
            "description": "1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9", 
            "intervention_name": "F-18-FCH & Ga-68-NODAGA-MJ9", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prostate cancer", 
            "primary", 
            "recurrence", 
            "F-18-FCH PET/CT", 
            "Ga-68-NODAGA-MJ9 PET/CT"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lausanne", 
                    "country": "Switzerland", 
                    "state": "Vaud", 
                    "zip": "1011"
                }, 
                "name": "Centre Hospitalier Universitaire Vaudois"
            }, 
            "investigator": {
                "last_name": "John O. Prior, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT", 
        "overall_contact": {
            "email": "john.prior@chuv.ch", 
            "last_name": "John O. Prior, MD, PhD", 
            "phone": "+41213144348"
        }, 
        "overall_official": {
            "affiliation": "CHUV, Lausanne, Switzerland", 
            "last_name": "John O. Prior, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PET images : SUVmax, SUVmean, VOI (mL), SUV41% lesions/ SUVbackground CT images : size lesions measured in 3D (axial, coronal and sagittal), density in Hounsfield Units (HU)", 
            "measure": "Positivity of the new radiotracer Ga-68-NODAGA-MJ9 compared to the standard radiotracer F-18-FCH", 
            "safety_issue": "No", 
            "time_frame": "At baseline (after F-18-FCH PET/CT)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111954"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Lausanne Hospitals", 
            "investigator_full_name": "John O. Prior", 
            "investigator_title": "Nuclear Medicine Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Lausanne Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Lausanne Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}